Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Suppression of invasion and metastasis in aggressive salivary cancer cells through targeted inhibition of ID1 gene expression.

Murase R, Sumida T, Kawamura R, Onishi-Ishikawa A, Hamakawa H, McAllister SD, Desprez PY.

Cancer Lett. 2016 Jul 10;377(1):11-6. doi: 10.1016/j.canlet.2016.04.021. Epub 2016 Apr 14.

2.

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

McAllister SD, Soroceanu L, Desprez PY.

J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. Review.

3.

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martinez-Martinez E, Amere M, Gujjar R, Mahadevan A, Desprez PY, McAllister SD.

Br J Pharmacol. 2014 Oct;171(19):4464-77. doi: 10.1111/bph.12803. Epub 2014 Sep 5.

4.

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.

Br J Pharmacol. 2014 Feb;171(3):636-45. doi: 10.1111/bph.12439.

5.

Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells.

Sumida T, Murase R, Onishi-Ishikawa A, McAllister SD, Hamakawa H, Desprez PY.

BMC Cancer. 2013 Mar 22;13:141. doi: 10.1186/1471-2407-13-141.

6.

Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, McAllister SD.

Cancer Res. 2013 Mar 1;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012 Dec 13.

7.

Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Murase R, Sumida T, Ishikawa A, Murase R, McAllister SD, Hamakawa H, Desprez PY.

Int J Otolaryngol. 2011;2011:187623. doi: 10.1155/2011/187623. Epub 2011 Nov 21.

8.

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY.

Breast Cancer Res Treat. 2011 Aug;129(1):37-47. doi: 10.1007/s10549-010-1177-4. Epub 2010 Sep 22. Erratum in: Breast Cancer Res Treat. 2012 May;133(1):401-4.

9.

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, Pakdel A, Allison J, Limbad C, Moore DH, Yount GL, Desprez PY, McAllister SD.

Mol Cancer Ther. 2010 Jan;9(1):180-9. doi: 10.1158/1535-7163.MCT-09-0407. Epub 2010 Jan 6.

10.

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY.

Mol Cancer Ther. 2007 Nov;6(11):2921-7.

11.

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, Aldape K, Yount G.

J Neurooncol. 2005 Aug;74(1):31-40.

PMID:
16078104
12.

Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation.

McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME.

J Biol Chem. 2004 Nov 12;279(46):48024-37. Epub 2004 Aug 23.

13.

Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.

Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Mar;5(1):33-9.

PMID:
15204022
14.

An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Abood ME.

J Med Chem. 2003 Nov 20;46(24):5139-52.

PMID:
14613317
15.

A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition.

McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, Reggio PH, Nowell Harmon KW, Cabral GA, Abood ME.

Biochem Pharmacol. 2002 Jun 15;63(12):2121-36.

PMID:
12110371
16.

CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.

McAllister SD, Glass M.

Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):161-71. Review.

PMID:
12052033
17.

Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

Abood ME, Rizvi G, Sallapudi N, McAllister SD.

Neurosci Lett. 2001 Aug 31;309(3):197-201.

PMID:
11514075
18.
19.

Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.

Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, Abood ME.

Eur J Pharmacol. 1999 Jul 14;377(1):117-25.

PMID:
10448934
20.

Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity.

Tao Q, McAllister SD, Andreassi J, Nowell KW, Cabral GA, Hurst DP, Bachtel K, Ekman MC, Reggio PH, Abood ME.

Mol Pharmacol. 1999 Mar;55(3):605-13.

Supplemental Content

Loading ...
Support Center